Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Infliximab, a mouse-human chimeric monoclonal antibody directed against tumour necrosis factor-alpha, has been shown to be effective for moderate to severe psoriasis, but there are few data published on its use in recalcitrant, treatment-resistant disease or in combination with other antipsoriatic therapies.

          Related collections

          Author and article information

          Journal
          Br. J. Dermatol.
          The British journal of dermatology
          Wiley-Blackwell
          0007-0963
          0007-0963
          Jul 2006
          : 155
          : 1
          Affiliations
          [1 ] Skin Therapy Research Unit, St John's Institute of Dermatology, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK. catherine.smith@kcl.ac.uk
          BJD7316
          10.1111/j.1365-2133.2006.07316.x
          16792769

          Comments

          Comment on this article